Categories Retail

Face-Off: Amazon’s facial recognition tool really messed up this time

Amazon’s (AMZN) facial recognition tool Rekognition misidentified 28 Congress members as illegal suspects. The tool was tested by the American Civil Liberties Union (ACLU) which, along with other civil rights advocates, have been rallying against Amazon demanding that the company refrain from selling the application to law enforcement agencies.

amazon facial recognition tool
(Image Courtesy: Pixabay)

In a test that cost just over $12, the ACLU compared the photos of all the US House and Senate members against a database of 25,000 mugshots. The results turned up matches for 28 Congress members with an accuracy level of around 80%. The matches also highlighted people of color more than others, giving strength to the arguments by civil rights groups that face-surveillance methods would unfairly target minorities and immigrants.

Civil rights activists have been arguing for long that methods of surveillance using facial recognition technology could be used unethically against minority communities, immigrants, activists or just about anyone with a viewpoint that is different from that of the government. ACLU wants Congress to prohibit law enforcers from using the technology on the grounds of it being faulty, biased and dangerous.

Amazon meanwhile stood by its product and blamed incorrect settings for the unflattering test results. Amazon said the 80% setting was more suited for the identification of objects and not for human beings and when being used in law enforcement for identifying people, a setting of 95% or higher was recommended.

Despite the criticism, Amazon believes the Rekognition tool can be used for crime prevention, tracking of missing individuals as well as several other worthy purposes. Facial recognition is popular in China for legal use with several companies investing in it significantly.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top